Betadine Baðlyf 75 mg/g Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

betadine baðlyf 75 mg/g

mundipharma a/s - povidonum iodinatum inn - baðlyf - 75 mg/g

Betadine Húðlausn 100 mg/ml Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

betadine húðlausn 100 mg/ml

mundipharma a/s - povidone, iodinated - húðlausn - 100 mg/ml

Betadine Húðlausn 100. mg/ml Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

betadine húðlausn 100. mg/ml

mundipharma a/s - povidone, iodinated - húðlausn - 100. mg/ml

Betadine Húðvökvi 100 mg/ml Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

betadine húðvökvi 100 mg/ml

mundipharma a/s - povidone, iodinated - húðvökvi - 100 mg/ml

Vildagliptin / Metformin hydrochloride Accord Euroopa Liit - islandi - EMA (European Medicines Agency)

vildagliptin / metformin hydrochloride accord

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - sykursýki, tegund 2 - lyf notuð við sykursýki - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 fyrir tiltæk gögn um mismunandi samsetningar).

Icandra (previously Vildagliptin / metformin hydrochloride Novartis) Euroopa Liit - islandi - EMA (European Medicines Agency)

icandra (previously vildagliptin / metformin hydrochloride novartis)

novartis europharm limited - vildagliptin, kvarta stutt og long-term - sykursýki, tegund 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 fyrir tiltæk gögn um mismunandi samsetningar).

Ledaga Euroopa Liit - islandi - EMA (European Medicines Agency)

ledaga

helsinn birex pharmaceuticals ltd. - chlormethine - mycosis fungoides - Æxlishemjandi lyf - ledaga er ætlað til staðbundinnar meðhöndlunar á t-frumu eitilæxli (mycosis fungoides-type t-cell lymphoma) hjá fullorðnum sjúklingum.

Galvus Euroopa Liit - islandi - EMA (European Medicines Agency)

galvus

novartis europharm limited - vildagliptin - sykursýki, tegund 2 - lyf notuð við sykursýki - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Jalra Euroopa Liit - islandi - EMA (European Medicines Agency)

jalra

novartis europharm limited - vildagliptin - sykursýki, tegund 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 fyrir tiltæk gögn um mismunandi samsetningar).

Xiliarx Euroopa Liit - islandi - EMA (European Medicines Agency)

xiliarx

novartis europharm limited - vildagliptin - sykursýki, tegund 2 - lyf notuð við sykursýki - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 fyrir tiltæk gögn um mismunandi samsetningar).